Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases... Show more
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SCHK | 36.76 | 0.27 | +0.74% |
| Schwab 1000 Index ETF (SCHK) | |||
| ETJ | 7.93 | 0.02 | +0.25% |
| Eaton Vance Risk - Managed Diversified Equity Income Fund | |||
| FFIU | 20.99 | 0.04 | +0.19% |
| UVA Unconstrained Medium-Term Fixed Income ETF (FFIU) | |||
| AGZD | 22.55 | -0.02 | -0.10% |
| WisdomTree Interest Rate Hedged U.S. Aggregate Bond Fund (AGZD) | |||
| YFYA | 9.64 | -0.04 | -0.41% |
| Yields for You Strategy A ETF | |||
A.I.dvisor indicates that over the last year, KNSA has been loosely correlated with COYA. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if KNSA jumps, then COYA could also see price increases.
| Ticker / NAME | Correlation To KNSA | 1D Price Change % | ||
|---|---|---|---|---|
| KNSA | 100% | -4.89% | ||
| COYA - KNSA | 42% Loosely correlated | +0.25% | ||
| ABVC - KNSA | 40% Loosely correlated | +0.96% | ||
| JBIO - KNSA | 37% Loosely correlated | -0.62% | ||
| AMRN - KNSA | 36% Loosely correlated | +2.54% | ||
| SNDX - KNSA | 35% Loosely correlated | -1.34% | ||
More | ||||
| Ticker / NAME | Correlation To KNSA | 1D Price Change % |
|---|---|---|
| KNSA | 100% | -4.89% |
| Pharmaceuticals category (153 stocks) | 1% Poorly correlated | +0.52% |
| Pharmaceuticals: Generic category (83 stocks) | 1% Poorly correlated | +1.08% |
a manufacturer of pharmaceutical products
Industry PharmaceuticalsGeneric
KNSA moved below its 50-day moving average on October 23, 2026 date and that indicates a change from an upward trend to a downward trend. In 23 of 30 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 77%.
The 10-day RSI Indicator for KNSA moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 48 similar instances where the indicator moved out of overbought territory. In 31 of the 48 cases, the stock moved lower in the following days. This puts the odds of a move lower at 65%.
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KNSA as a result. In 69 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.
The Moving Average Convergence Divergence Histogram (MACD) for KNSA turned negative on October 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 27 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 63%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KNSA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
The Aroon Indicator for KNSA entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The 10-day moving average for KNSA crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
Following a +5.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where KNSA advanced for three days, in 232 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
KNSA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Profit vs. Risk Rating rating for this company is 3 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. KNSA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.705) is normal, around the industry mean (8.413). P/E Ratio (68.849) is within average values for comparable stocks, (-1.728). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (7.564) is also within normal values, averaging (178.797).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.